Innate Pharma has always wanted to follow the best practices in corporate governance. The company set up a Scientific Advisory Board in 2000, a Compensation Committee in 2001 as well as an Audit Committee in 2003.
In 2005, Innate Pharma was transformed into a SA with a dual management mode: an Executive Board controlled by a Supervisory Board.

The company uses a network of reference independent experts to receive advise on all operating matters, from accounting to medical development.

The Executive Board is in charge of administrative, legal and financial operations of the company.
It operates under the control of the Supervisory Board.

The Executive Committee - a non-statutory body - manages the company daily operations. Members of the Executive Board are also part of this committee.

The Supervisory Board controls the Executive Board in its management of the company.
Its members have a great deal of experience in the biopharmaceutical sector.


Governance Committees

To date, the Supervisory Board has four sub-committees:

• the compensation and nomination committee,
• the audit committee,
• the transaction committee and
• the scientific committee.

All four committees report to the Supervisory Board.


Independant experts

The company regularly collaborates with independent experts who provide advice on accounting, business strategy, development operations, clinical strategy and regulatory affairs.


Internal control

In accordance with the French commercial code, the Chairman of the Supervisory Board drafted a report on the company's internal control procedures.
In accordance with the same regulation, the Company auditors drafted a report on the Chairman's report..